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aged mice and enhances fracture healing
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Deye Song1,2, Guangxu He1,2, Fangfang Song3, Zhepeng Wang2, Xiaochen Liu2, Lele Liao1, Jiangdong Ni1, Matthew J. Silva2 and
Fanxin Long 2,3
There remain unmet clinical needs for safe and effective bone anabolic therapies to treat aging-related osteoporosis and to
improve fracture healing in cases of nonunion or delayed union. Wnt signaling has emerged as a promising target pathway for
developing novel bone anabolic drugs. Although neutralizing antibodies against the Wnt antagonist sclerostin have been tested,
Wnt ligands themselves have not been fully explored as a potential therapy. Previous work has demonstrated Wnt7b as an
endogenous ligand upregulated during osteoblast differentiation, and that Wnt7b overexpression potently stimulates bone accrual
in the mouse. The earlier studies however did not address whether Wnt7b could promote bone formation when speciﬁcally applied
to aged or fractured bones. Here we have developed a doxycycline-inducible strategy where Wnt7b is temporally induced in the
bones of aged mice or during fracture healing. We report that forced expression of Wnt7b for 1 month starting at 15 months of age
greatly stimulated trabecular and endosteal bone formation, resulting in a marked increase in bone mass. We further tested the
effect of Wnt7b on bone healing in a murine closed femur fracture model. Induced expression of Wnt7b at the onset of fracture did
not affect the initial cartilage formation but promoted mineralization of the subsequent bone callus. Thus, targeted delivery of
Wnt7b to aged bones or fracture sites may be explored as a potential therapy.
Bone Research (2020)8:4
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INTRODUCTION
The adult human skeleton is a dynamic organ that undergoes
continuous remodeling throughout life to support whole-body
mineral homeostasis while sustaining structural integrity. Healthy
remodeling requires the balancing activities of bone resorption by
osteoclasts and bone formation by osteoblasts.1 Loss of the
balance in favor of bone resorption causes a net bone loss,
resulting in osteopenia or in the more severe cases osteoporosis, a
hallmark of aging. The current therapeutics for osteoporosis
include two bone anabolic agents, namely teriparatide and
abaloparatide, both recombinant proteins that activate the
parathyroid hormone receptor PTH1R.2 However, the clinical use
of those drugs is limited due to unresolved concerns about
osteosarcoma.3 Thus, additional bone anabolic therapies are
necessary to fulﬁll the unmet needs among osteoporotic patients.
Such new therapies are also needed to promote bone fracture
healing which is often negatively impacted by aging and
diabetes.4,5
Wnt signaling has emerged as a promising target pathway for
developing new bone anabolic drugs.6,7 Wnt proteins are a family
of secreted glycoproteins that signal through cell-surface receptors including the frizzled proteins and the low-density lipoprotein
receptor-related protein Lrp5 or Lrp6.8 Wnt signaling is ﬁne-tuned
by various extracellular modulators, including the secreted
antagonist sclerostin (encoded by the Sost gene), that compete

with Wnt proteins for binding to Lrp5/6.9 Genetic evidence has
demonstrated that inhibitory or activating mutations of LRP5 in
humans cause osteoporosis-pseudoglioma (OPPG) or high-bonemass syndromes, respectively, whereas deletion or loss of
expression of Sost results in osteosclerosis.10–14 In addition,
deﬁciency of WNT1 has been linked to inherited early-onset
osteoporosis or osteogenesis imperfecta in patients,15–18 whereas
WNT16 has been repeatedly associated in genome-wide association studies with bone mineral density (BMD), cortical bone
thickness, and nonvertebral fractures.19,20 Those ﬁndings thus
establish Wnt signaling as an essential bone-promoting mechanism and raise the potential that the pathway may be targeted for
developing bone anabolic drugs. Indeed, a humanized monoclonal antibody against sclerostin, known as Romosozumab
(ROMO), has recently been approved for clinical use. Potential
pharmaceutical use of Wnt proteins per se however has not been
fully explored.
Wnt7b has been implicated in the stimulation of bone
formation. In the developing long bones of the mouse, Wnt7b is
enriched in the osteogenic perichondrium (PC) ﬂanking the
hypertrophic cartilage but declines in the more mature osteoblasts, indicating transient upregulation of Wnt7b during osteoblast differentiation in vivo.21,22 Wnt7b has also been shown to
increase with osteoblast differentiation of calvarial cells in vitro.23
Functionally, Wnt7b deletion in the osteogenic progenitors of the
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mouse causes a temporary delay in ossiﬁcation but the defect is
later resolved perhaps due to compensation by the other Wnt
proteins.21 In adult bone, Wnt7b expression appears to be minimal
but it is induced by mechanical loading.24 Importantly, the extent
of Wnt7b induction declines with aging and may underlie the
muted bone anabolic response to mechanical loading in the aged
mice.24 Aging also reduces WNT7B expression in human bone
marrow (BM) stromal cells, indicating that the decline of Wnt7b
expression in osteoblast lineage cells may contribute to the
diminution of bone formation activity associated with aging.25
These ﬁndings raise the interesting possibility that supplying
additional Wnt7b may help to rejuvenate aged bone. We have
previously reported that overexpression of Wnt7b in the
osteoblast lineage potently stimulates bone formation in adult
mice by increasing both osteoblast number and activity.26 That
work however relied on sustained expression of Wnt7b beginning
in the embryo and could not discern a potential bone anabolic
effect speciﬁcally in the aged bone.
Here we report that temporal induction of Wnt7b expression in
the aged mouse bones exerts a potent bone anabolic function.
Furthermore, postfracture application of Wnt7b notably stimulates
mineralization of the bone callus. These results therefore provide
proof of principle that Wnt7b protein may be explored as a bone
anabolic therapy.
RESULTS
Generation of the Osx-rtTA mouse
To create a mouse genetic tool that allows for temporal control of
gene expression in the osteoblast lineage, we set out to create a
transgenic mouse (termed Osx-rtTA) expressing the reverse
tetracycline transactivator (rtTA) from the Osx locus. Brieﬂy, an
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Osx BAC (bacterial artiﬁcial chromosome) was modiﬁed to replace
the ﬁrst exon of Osx with the cDNA for rtTA, and then used to
produce transgenic mice through pronuclear injection (Fig. 1a).
The founder animals carrying the Osx-rtTA transgene were mated
with the tetO-Cre and the mT/mG mice to produce triple
transgenic animals with the genotype of Osx-rtTA;tetO-Cre;mT/
mG, which were tested for green ﬂuorescence protein (GFP)
expression in response to doxycycline (Dox) added to either the
food or the drinking water (Fig. 1b). Two founders were found to
produce triple transgenic progenies that express Cre activity in
skeletal tissues only in the presence of Dox. As the two founders
exhibited similar expression patterns, we present here the data
from only one of them (line 4) and propagated this line for
subsequent studies. When the Osx-rtTA;tetO-Cre;mT/mG embryos
were exposed to Dox throughout embryogenesis and analyzed at
birth, GFP was readily detected in the bone shaft of long bones
(Fig. 1c). At a higher magniﬁcation, GFP was notable within the
primary spongiosa (1°) and at the PC ﬂanking the hypertrophic
zone, both of which are known to undergo active osteoblastogenesis at this stage (Fig. 1d). GFP was also detectable in the
hypertrophic chondrocytes (HC), indicating that the BAC transgene recapitulated the normal expression pattern of Osx in
skeletal cells, including that in the embryonic HC (Fig. 1d).27 No
GFP was detected in tendons, ligaments, skeletal muscle, or
marrow fat. Outside the skeleton, GFP was not detected in the
brain, intestine, heart, lung, or liver either in whole-mount or on
sections. When the triple transgenic mice were exposed to Dox
from birth to 1 month of age, GFP was found to decorate all bone
surfaces in both the primary (1°) and secondary (2°) ossiﬁcation
centers, as well as those of the cortical bone (CB) (Fig. 1e–g).
However, the growth plate (GP) including the hypertrophic zone
no longer expressed GFP when Dox was applied postnatally
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Fig. 1 Generation and validation of the Osx-rtTA transgenic mouse. a Generation of Osx-rtTA. b Validation of the transgenic mouse by
crossing with tetO-Cre and mT/mG mice. In b, the rtTA protein expressed by the Osx-rtTA transgene, upon binding to doxycycline (Dox)
supplied through the diet, activate expression of Cre, which in turn recombine the mT/mG allele to convert expression of membrane-tethered
tdTomato (mT) to membrane-tethered eGFP (mG). c, d Direct visualization of GFP and RFP on sections of the forelimb from Osx-rtTA;tetO-Cre;
mT/mG mice receiving Dox from conception to harvest at birth. Note GFP speciﬁcally in metaphysis and diaphysis of the humerus (c). Asterisk
indicates artifactual detachment of tissue. At higher magniﬁcation (d), GFP was detected in the perichondrium (PC), the hypertrophy cartilage
(HC), and the primary spongiosa (1°). e–g Sections of the tibia from Osx-rtTA;tetO-Cre;mT/mG mice receiving Dox from birth to 1 month of age
when the mice were harvested. Note GFP on bone surfaces of primary (1°), secondary (2°) ossiﬁcation centers, and the cortical bone (CB), but
not in the growth plate (GP). Sections of the tibia from Osx-rtTA;tetO-Cre;mT/mG mice with (h, i) or without (j, k) Dox from 45 days of age for
1 week before harvest. Note that the bone marrow proper (BM) was largely negative for GFP except for the occasional stromal cells
(arrowheads) in the +Dox mouse (i).
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Fig. 2 Activation of Wnt7b in aged mice increases bone mass. a RT-qPCR analyses of Wnt7b mRNA in the bones of mice treated with Dox for
2 weeks starting at 4 weeks of age. Ctrl: Osx-rtTA;R26-Wnt7b mice; Wnt7b: Osx-rtTA;tetO-Cre;R26-Wnt7b mice. *P < 0.05, n = 3. b Whole-body
(excluding head) DXA analyses of bone mineral content (BMC) and bone mineral density (BMD) of Osx-rtTA;tetO-Cre;R26-Wnt7b mice with or
without Dox treatment from 15 through 16 months of age. *P < 0.05, one-way ANOVA, n = 5 (four males, one female). c Contact X-ray images
representative of the hindlimbs at time of sacriﬁce. Error bars: stdev in all ﬁgures.

(Fig. 1e). When the triple transgenic mice were treated with Dox
for 1 week starting at 45 days of age, GFP was also largely
restricted to the primary (1°) and secondary (2°) ossiﬁcation
centers together with the CB, with the exception of occasional
signals in some stromal cells of the BM (Fig. 1h, i). The activity was
strictly dependent on Dox as triple transgenic mice without Dox
exposure expressed no GFP in the skeleton (Fig. 1j, k). Thus, the
Osx-rtTA transgenic mouse can be used for temporal manipulation
of gene expression in the osteoblast lineage through the use of
Dox.
Expression of Wnt7b in aged bones increases bone mass
To conﬁrm the efﬁcacy of Osx-rtTA in activating Wnt7b expression
in bone, we mated the Osx-rtTA mouse with the tetO-Cre and the
R26-Wnt7b mice to generate triple transgenic progenies with the
genotype of Osx-rtTA;tetO-Cre;R26-Wnt7b, with one copy of each
transgene. The triple transgenic mice, together with Osx-rtTA;R26Wnt7b littermate control, were subjected to Dox treatment for
2 weeks beginning at 4 weeks of age before RNA was harvested
from the long bones. RT-qPCR showed that Wnt7b was overexpressed by ~26-fold in the triple heterozygous over the control
mice, indicating effective activation of the R26-Wnt7b allele by
Osx-rtTA in bone (Fig. 2a). We next set out to test the potential
effect of Wnt7b on aged bones. The triple transgenic mice were
raised until 15 months of age with regular chow before being
randomly divided into two groups with or without Dox added to
the food for 1 month before sacriﬁce (Fig. 2b). The bone
parameters were collected with dual energy X-ray absorptiometry
scan (DXA) and in vivo micro-computed tomography (vivaCT)
immediately before and after the Dox regimen. DXA indicated that
Dox markedly increased both bone mineral content and BMD in
the mice after 1 month of treatment, whereas those parameters
remained constant in the control mice (−Dox) during the same
period (Fig. 2b). Contact X-ray radiography conﬁrmed that the
bones of animals receiving Dox (+Dox) exhibited much greater
density than those without Dox (−Dox) (Fig. 2c). 3D reconstruction
of the CB from vivaCT scans of the tibia demonstrated that Dox
caused a marked thickening of the cortex, resulting in virtual
occlusion of the marrow space (Fig. 3a). Quantiﬁcation of the CT
data revealed that, whereas the overall size of the tibia (Tt.Ar) was
not changed, the CB area (Ct.Ar) and thickness (Ct.Th) were
signiﬁcantly increased, thus greatly diminishing the BM space (Ma.
Ar) in the +Dox group (Fig. 3b). Similarly, the trabecular bone of
the distal femur was notably increased by Dox, as evident in the
Bone Research (2020)8:4

3D reconstruction images (Fig. 3c). Quantitative analyses indicated
that the increase in bone mass (BV/TV) was largely caused by
thickening of the bone trabeculae in response to Dox (Fig. 3d).
Thus, induction of Wnt7b expression in the aged bones for
1 month notably increases both cortical and trabecular bone mass.
Wnt7b stimulates bone formation in aged mice
To determine the cellular basis for the increased bone mass by
Wnt7b, we performed biochemical assays with sera collected from
the mice at the time of sacriﬁce. The bone formation marker P1NP
(procollagen type I amino-terminal propeptide) was increased by
an average of eightfold, whereas the bone resorption marker CTX1 (carboxyl-terminal telopeptide of collagen type I) was also
elevated by ~2.5-fold by Dox (Fig. 4a, b). Thus, bone formation was
clearly activated relative to resorption and thus responsible for the
overall increase in bone mass in response to Wnt7b.
We next performed histomorphometry for a better understanding of the bone phenotype. Hematoxylin and eosin (H&E)
staining of femoral sections conﬁrmed the presence of more
cancellous bone in both primary (1°) and secondary (2°)
ossiﬁcation centers, and also thicker CB in the +Dox mice
(Fig. 4c, d). A closer examination of the CB indicated that Dox
caused a trend of increase in osteocyte density even though the
change did not reach statistical signiﬁcance (n = 3, P = 0.054)
(Fig. 4e). To monitor the bone forming activity directly, we
conducted double labeling experiments before the harvest of the
animals. Images of the sections indicated a notable increase in the
extent and intensity of ﬂuorescence labeling on endosteal,
trabecular, and periosteal bone surfaces (Fig. 4f–h). Quantiﬁcation
of the labeled surfaces conﬁrmed that mineral apposition rate was
markedly increased on all three bone surfaces, even though our
earlier vivaCT analyses did not detect a statistically signiﬁcant
increase in periosteal growth (Fig. 4i–k). Overall, Wnt7b exhibits a
potent bone forming activity in both trabecular and CB compartments of aged mice.
Wnt7b enhances bone healing
We next sought to examine the effect of Wnt7b on bone healing
in a closed femoral fracture model. Brieﬂy, mice with the genotype
of Osx-rtTA;tetO-Cre;R26-Wnt7b were raised on a regular diet until
10 weeks of age when a fracture was introduced at the diaphysis
of the right femur of each mouse; the mice were then randomly
assigned to two groups with or without Dox supplement in the
diet, and allowed to heal for up to 21 days (Fig. 5a). Contact X-ray
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radiography immediately following the procedure conﬁrmed a
complete fracture at the middle point of the femur and the proper
stabilization by a metal pin (Fig. 5b, upper). After 7 days of healing
when an unmineralized cartilage callus normally forms, no
“bridging” of the fracture was detected by X-ray regardless of
the Dox treatment (Fig. 5b, lower). Histology of the femoral
sections showed an obvious cartilage callus surrounding the
fracture site regardless of Dox (Fig. 5c). Measurements of the
cartilage callus area on sections indicated no difference in the
callus size between the groups (Fig. 5d). No bony covering or
encroachment of the cartilage callus was evident in the Doxtreated mice. However, excessive bone formation was noted in the
distal medullary space next to the metal pin in response to Dox,
indicating that Wnt7b was induced and functional in the femur at

this 7-day time point (Fig. 5c). Thus, application of Wnt7b at the
onset of fracture healing does not affect the early healing
responses including cartilage callus formation.
To assess the potential effects of Wnt7b on the later stages of
fracture healing, we examined the bones at day 14 or 21 after
fracture. At day 14 (D14), the fracture site normally contains a
large osteochondral callus, with cartilage tissue starting to be
replaced by bone, whereas day 21 (D21) is nearing completion of
the cartilage-to-bone transition. At D14, X-ray radiography
detected a marked increase in the radiodensity of the bony callus
along with the rest the femur in the Dox-treated mice (Fig. 6a).
MicroCT imaging of the fracture site conﬁrmed the presence of a
more contiguous bony callus across the fracture site in the +Dox
mice (Fig. 6b). Quantiﬁcation of the microCT data showed that
Bone Research (2020)8:4
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although the overall callus volume did not signiﬁcantly differ
between the groups, the callus BMD was higher in the Dox group,
indicating relatively more mineralized bone in the callus, a
measure for accelerated healing (Fig. 6c). Similarly, at D21,
microCT imaging showed that the bone bridging across the
fracture site was more complete in the Dox-treated animals
(Fig. 6d). The callus BMD became markedly higher in the +Dox
group than the control, even though the overall callus size
remained the same (Fig. 6e). Overall, Wnt7b stimulates mineralization of the bone callus with no obvious effect on the callus size.
DISCUSSION
We have developed a doxycycline-inducible system to manipulate
gene expression in the osteoblast lineage of the mouse. By
temporally activating Wnt7b expression in aged mice, we show
that Wnt7b potently stimulates bone formation and leads to a
marked increase in bone mass. We further demonstrate that
Wnt7b promotes bone mineralization during fracture healing. The
present work therefore provides evidence that targeted delivery
of Wnt7b may be a potential therapy for osteoporosis and
recalcitrant fractures.
Studies of gene function at speciﬁc embryonic or postnatal
stages require genetic tools that can be controlled temporally.
Previously, the Osx-Cre mouse strain was designed to express Cre
in the osteoblast lineage in the absence of Dox.28 With that model,
temporal gene manipulation speciﬁcally in postnatal mice requires
long-term exposure of mice to Dox that begins in utero and
extends till the stage when Cre activity is desired, as exempliﬁed
by a previous study.29 Long-term usage of Dox can be
Bone Research (2020)8:4

cumbersome, and more importantly may directly impact the
skeleton.30 In addition, Osx-Cre may need extended “washout”
time following the withdrawal of Dox in order for Cre to be
expressed due to the high afﬁnity of Dox for bone minerals.31 The
Osx-rtTA transgene created here operates by the opposite design,
where rtTA is expressed in the osteoblast lineage cells but becomes
active only when Dox is provided. The Osx-rtTA transgene offers the
ﬂexibility of combining with either tetO-Cre for Cre/loxP-based
genomic deletion, or other tetO-driven transgenes for direct
overexpression of the desired gene. The new system therefore
offers a useful tool for inducible genetic studies in bone.
The present study provides further evidence for the potent
bone anabolic activity of Wnt7b. Although previous work has
documented the strong osteogenic activity of Wnt7b when it is
continuously overexpressed from embryogenesis onward, the
current results provide the ﬁrst evidence that Wnt7b application in
aged bones markedly stimulates bone formation.22,26 The bone
forming activity was most robust in the trabecular and endosteal
bone surfaces, resulting in a notable increase in both cancellous
and CB mass. Wnt7b also activated bone formation on the
periosteal surface, but did not cause a statistically signiﬁcant
increase in the overall size of the long bones according to vivaCT,
perhaps due to the relatively short duration of Wnt7b expression
and the insufﬁcient power of the sample size. In any case, the
anabolic response to Wnt7b at the periosteum is clearly lesser
than that at the trabecular or endosteal bone surface, and is in
keeping with our previous observation in mice with continuous
expression of Wnt7b in bone up to 2 months of age.26 Similarly,
transgenic mice overexpressing Wnt16 in osteoblasts in two
independent studies also did not increase the outer circumference
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Fig. 6 Wnt7b enhances mineralization of the bone callus. a Representative X-ray radiographs of femurs immediately following fracture (D0)
and at 14 days afterwards (D14). Representative 3D reconstruction images (b) and quantiﬁcation from microCT scans (c) of bone calluses at
D14. *P < 0.05, Student’s t test, n = 7 or 6 for −Dox or +Dox groups, respectively. Reconstruction images (d) and quantiﬁcation from microCT
scans (e) of bone calluses at D21. *P < 0.05, Student’s t test, n = 3.

of the bone shaft in long bones although one study showed an
increase in endosteal bone growth.32,33 On the other hand, the
injection of a sclerostin monoclonal antibody in 4-month-old mice
for 5 weeks was shown to increase the overall bone size.34 Thus,
Wnt proteins other than Wnt7b and Wnt16 may preferentially
stimulate periosteal growth under normal conditions. Mice
overexpressing Wnt10 or Wnt1 in bone have also been shown
to increase bone mass but the effect on periosteal growth was not
quantiﬁed in those studies.35,36 Our Wnt7b overexpression model
described here is most comparable to that of Wnt1, as both
proteins are expressed from a Rosa26 knockin allele (R26-Wnt7b
or R26-Wnt1, respectively) upon Cre recombination. Activation of
R26-Wnt7b or R26-Wnt1 in bone dramatically increases bone mass
mainly through activation of trabecular and endosteal bone
formation, and in both case mTORC1 signaling partially mediates
the anabolic function.26,35 In both models, the overall bone
resorption activity as indicated by the serum CTX-1 levels is
increased over the control, even though the osteoclast number
normalized to bone surface is reduced in the Wnt7b overexpression model.26 In contrast, serum CTX-1 levels were
suppressed by sclerostin antibodies in both mice and in humans,
indicating that Wnt proteins other than Wnt1 and Wnt7b play a
more prominent role in suppressing bone resorption.34,37 Wnt16 is
a potential contributor in this regard as Wnt16 deletion led to
increased bone resorption in the mouse although mice overexpressing Wnt16 in osteoblasts exhibited normal serum CTX-1
levels.32,38 A limitation of the R26-Wnt1 or the R26-Wnt7b mouse
model is that once activated by Cre, the expression of the Wnt
protein is permanent. Thus, a future reversible model would be
necessary in order to determine the state of bone modeling after
the cessation of Wnt treatment. At least two other Wnt proteins,
namely Wnt5a and Wnt4, were overexpressed in bone from the
Rosa26 locus, but neither was reported to increase bone mass in
the mouse.26,39 Thus, Wnt7b and Wnt1 are among the most
potent bone-inducing Wnt proteins known to date.

Our fracture studies show that Wnt7b increases the mineral
density of the bone callus without affecting the initial size of the
cartilage callus. We did not detect a statistically signiﬁcant
increase in the total callus size by microCT at either D14 or D21.
Thus, Wnt7b appears to mainly enhance formation and/or
mineralization of the bone matrix, but future double labeling
experiments would be necessary to determine whether Wnt7b
increases bone formation rate in the callus. Future mechanical
testing studies are also needed to determine whether Wnt7b
improves the fracture site strength at the later time points. The
fact that Wnt7b did not affect the formation of cartilage callus is
worth noting. As Wnt/β-catenin signaling is known to inhibit
chondrogenesis, the result is consistent with previous ﬁndings
that Wnt7b signals largely through β-catenin-independent pathways.21,26,40 Different from Wnt7b, PTH has been shown to
increase cartilage callus formation in fracture studies.41 Thus, in
clinical settings, Wnt7b may be most useful in cases where the
initial healing is relatively normal but the subsequent ossiﬁcation
is impaired or delayed.
Although ROMO, a humanized monoclonal antibody against
sclerostin, was recently approved for osteoporosis treatment, it
carries a black box warning against increased risk of cardiovascular
events.42 Considering ROMO likely increases signaling by multiple
Wnt proteins which may have nonoverlapping functions, targeting
speciﬁc Wnt ligands such as Wnt7b may afford an opportunity to
achieve the bone anabolic function while avoiding the unwanted
side effects.
MATERIALS AND METHODS
Mouse strains
All procedures with mice were approved by the Animal Studies
Committee at Washington University in St. Louis School of
Medicine, or the IACUC committee at the Children’s Hospital of
Philadelphia. The tetO-Cre mice and the mT/mG mice were
Bone Research (2020)8:4
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purchased from the Jackson Laboratories.43,44 The R26-Wnt7b
mouse strain was generated as previously described.26 Both males
and females were included in the study.
To generate the Osx-rtTA transgene, we modiﬁed a Osx BAC
(bacterial artiﬁcial chromosome, clone# RP23-399N14) (Children’s
Hospital of Oakland Research Institute) to replace the ﬁrst exon of
Osx with the cDNA for rtTA2S-M2.45 Brieﬂy, a 491 bp PCR amplicon
immediately upstream of the Osx starting ATG (forward primer: 5′
CTACCCAGGTACAGACACT GGGCAGTTCTG3′; reverse primer: 5′
CCTCGAGCTGGGGACCGGGTCCCAAGGAGT3′), the cDNA for
rtTA2S-M2 excised from pUHrT62-1,45 and a 367 bp PCR amplicon
located ~100 bp downstream of the Osx starting ATG (forward
primer: 5′ ATCCTCACATCGACA GGAGCTGCAATGCTAGTC3′;
reverse primer: 5′ CTCTTTCCTCAACACAGACCTGACCAGATC 3′)
were inserted into the pSV-Flp vector. The resulted plasmid was
digested with restriction enzymes to release the targeting
construct. Subsequent BAC recombineering was performed as
described.46–48 Correctly targeted BACs were conﬁrmed by
directional PCR, restriction digestion, and sequencing. The ﬁnished
Osx-rtTA BAC transgene is prepared for microinjection by modiﬁed
Qiagen maxi-prep followed by dot dialysis of the circular BAC.
Transgenic mice were produced by pronucleus injection at the
Washington University Mouse Genetics Core. Seven founders were
produced and were individually crossed with tetO-Cre and mT/mG
mice to produce triple transgenic mice with or without
doxycycline-containing drinking water (500 μg·mL−1, 2% sucrose)
or food (200 mg·kg−1 food, Bioserv S3888). Bones and various
internal organs were ﬁxed with 4% paraformaldehyde overnight at
4 °C and subjected to cryostat sectioning. The adult bones were
decalciﬁed with 14% EDTA on a shaker for 3 days with daily
change of solutions, and sectioned with the aid of Cryojane. GFP
or RFP was directly visualized under a ﬂuorescence microscope
(NIKON ECLIPSE E800) equipped with a QImaging Retiga 2000R
CCD camera. Founder mice that produced progenies expressing
GFP in the absence of Dox or failed to express GFP speciﬁcally in
skeleton were eliminated. Two founders exhibited the desired
inducibility and speciﬁcity, and also stably transmitted the
transgene through germline. Line 4 was chosen for further studies.
RT-qPCR
Femurs and tibias were harvested from Osx-rtTA;tetO-Cre;R26Wnt7b or Osx-rtTA; R26-Wnt7b littermate mice fed with Dox food
for 2 weeks starting at 4 weeks of age. The bone shafts were
collected in 1 mL Trizol (Thermo Fisher Scientiﬁc) after the GPs
were surgically removed and the BM discarded by centrifugation.
The bone shafts were homogenized with Precellys Evolution
homogenizer (Bertin Instruments) and then extracted for RNA with
the QIAGEN RNeasy Kit (#74104). RT-qPCR was performed with
SuperScript™ VILO™ cDNA Synthesis Kit (11754050), followed by
Power SYBR™ Green RNA-to-CT™ 1-Step Kit in a QuantStudio3
machine (Applied Biosystems). β-actin was used as internal
control. The PCR primers are as follows: Wnt7b: 5′caatggtggtctggtacccaa3′, 5′agtctcatggtccctttgtggtt3′; β-actin: ′GTGACGTTGA
CATCCGTAAAGA3′, 5′GCCGGACTCATCGTACTCC3′.
Bone morphometric studies
To monitor bone accretion with time, in vivo microCT (vivaCT 40;
Scanco Medical) was used to scan the femurs and tibia in live
mice, with the settings of 21 μm voxel size, 55 kVp, 145 μA, and
300 ms integration time. For quantifying trabecular bone parameters, 30 slices (0.6 mm total) immediately proximal to the distal
femoral GP were analyzed (threshold set at 160). For quantifying
CB parameters, 50 slices (1.0 mm total) starting at 5 mm above the
tibia–ﬁbular junction were analyzed (threshold set at 250). DXA
scans and X-ray radiography were performed with Faxitran Model
UltraFocus 100 (Tucson, AZ).
For histology, bones were ﬁxed in 10% buffered formalin
overnight, and then decalciﬁed in 14% EDTA for 2 weeks. The
Bone Research (2020)8:4
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decalciﬁed bones were processed, embedded in parafﬁn and
then sectioned at 6 μm thickness for H&E staining. For double
labeling, calcein and alizarin were injected intraperitoneally at
20 mg·kg−1 at day 7 and 2, respectively, before the mice were
sacriﬁced (Sigma, St. Louis, MO, USA). The bones were then ﬁxed
in 70% ethanol and processed for sectioning in methylmethacrylate. Quantiﬁcation of the histomorphometric parameters was performed with a Bioquant software (Nashville,
TN, USA).
Serum CTX-I and P1NP assays
For serum cross-linked C-telopeptide (CTX-I) and amino-terminal
propeptide of type I procollagen (P1NP) assays, serum was
collected from mice after 6 h of fasting. Assays were performed
with RatLaps ELISA or Rat/Mouse P1NP EIA kit (both from
Immunodiagnostic Systems, Ltd.).
Bone fracture studies
Bone healing studies were performed with 10-week-old mice by
using a closed femoral fracture model as previously described.49
Brieﬂy, anesthetized mice were prepared for surgery by shaving
the fur around the knee area and disinfecting the skin with
Betadine. An incision was made at the right knee to dislocate the
patella and the intramedullary canal was accessed by creating a
hole in the distal end of the femur. A guidewire was placed into
the femur and the mouse secured into custom three-point
bending ﬁxtures on a materials-testing machine (Dynamight 8841,
Instron). The femur was fractured at the mid-diaphysis by
application of a controlled transverse displacement. Then the
femur was stabilized with a 24-gauge stainless steel pin that was
positioned over the guidewire. The guidewire was removed, the
rod trimmed and the wound sutured closed. Animals were given
Buprenex to alleviate any pain. X-ray radiographs were taken with
20 s exposures at 25 kV immediately following surgery and prior to
sacriﬁce to conﬁrm pin stability (Faxitran UltraFocus 100, Tucson,
AZ). If the radiograph showed displacement of the pin, the femur
was excluded from all analyses.
The fractured femurs were analyzed at 7, 14, or 21 days after
surgery. The femurs were ﬁxed in 10% neutral buffered formalin at
room temperature overnight, rinsed with PBS, and preserved in
70% ethanol until use. For CT scans, the femurs were embedded in
2% agarose and scanned with the settings of 21 μm voxel size,
55 kVp, 145 μA, and 300 ms integration time (VivaCT, Scanco
Medical AG, Switzerland). The region of interest was deﬁned as
300 slices (6.3 mm) centered at the fracture midpoint and
encompassing the whole callus. A threshold of 150/1 000 was
set for all mineralized tissue, whereas a threshold of 460/1 000 was
set for the CB only. Callus volume and callus BMD were calculated
as previously described.49 After CT scanning, the bones were
decalciﬁed, embedded in parafﬁn, and sectioned at 6 μm
thickness. For quantiﬁcation of the cartilage callus, images of
the H&E-stained sections were captured with Nanozoomer
(Hamamatsu Photonics) and the cartilage area was measured
with the NDP software.
Statistics
Quantitative data were evaluated by Student’s t test or one-way
ANOVA as indicated in ﬁgure legends. P < 0.05 was considered
statistically signiﬁcant.
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